Section of Electrophysiology, Division of Cardiology, Emory University, Atlanta, Georgia, USA.
J Cardiovasc Electrophysiol. 2021 Feb;32(2):484-490. doi: 10.1111/jce.14825. Epub 2020 Dec 7.
Data on the management of Micra transcatheter pacing system (TPS) at the time of an upgrade or during battery depletion is limited.
We sought to evaluate the management patterns of patients implanted with a Micra TPS during long-term follow-up.
We retrospectively identified patients who underwent Micra implantation from April 2014 to November 2019. We identified patients who underwent extraction (n = 11) or had an abandoned Micra (n = 12).
We identified 302 patients who received a Micra during the period of the study. Mean age was 72.7 ± 15.4 years, 54.6% were men, and left ventricular ejection fraction was 51.9 ± 5.2%. Mean follow-up was 1105.5 ± 529.3 days. Procedural complications included pericardial tamponade (n = 1) treated with pericardiocentesis, significant rise in thresholds (n = 6) treated with reimplantation (n = 4), and major groin complications (n = 2). Indications for extraction included an upgrade to cardiac resynchronization therapy (CRT) device (n = 3), bridging after extraction of an infected transvenous system (n = 3), elevated thresholds (n = 3), and non-Micra-related bacteremia (n = 2). The median time from implantation to extraction was 78 days (interquartile range: 14-113 days), with the longest extraction occurring at 1442 days. All extractions were successful, with no procedural or long-term complications. Indications for abandonment included the need for CRT (n = 6), battery depletion (n = 2), increasing thresholds/failure to capture (n = 3), and pacemaker syndrome (n = 1). All procedures were successful, with no procedural or long-term complications.
In this large single-center study, 6% of patients implanted with a Micra required a system modification during long-term follow-up, most commonly due to the requirement for CRT pacing. These patients were managed successfully with extraction or abandonment.
目前有关升级或电池耗竭时管理 Micra 经导管起搏系统(TPS)的数据有限。
我们旨在评估长期随访中植入 Micra TPS 的患者的管理模式。
我们回顾性地确定了 2014 年 4 月至 2019 年 11 月期间接受 Micra 植入的患者。我们确定了 11 例进行了提取的患者和 12 例被放弃的 Micra 患者。
研究期间共确定了 302 例接受 Micra 治疗的患者。平均年龄为 72.7±15.4 岁,54.6%为男性,左心室射血分数为 51.9±5.2%。平均随访时间为 1105.5±529.3 天。手术并发症包括心包填塞(1 例,经心包穿刺治疗)、阈值显著升高(6 例,经再植入治疗 4 例)和主要腹股沟并发症(2 例)。提取的适应证包括升级为心脏再同步治疗(CRT)装置(3 例)、提取感染性经静脉系统后的桥接(3 例)、阈值升高(3 例)和非 Micra 相关菌血症(2 例)。从植入到提取的中位数时间为 78 天(四分位距:14-113 天),最长提取时间为 1442 天。所有提取均成功,无手术或长期并发症。放弃的适应证包括需要 CRT(6 例)、电池耗竭(2 例)、阈值升高/无法捕获(3 例)和起搏器综合征(1 例)。所有手术均成功,无手术或长期并发症。
在这项大型单中心研究中,6%植入 Micra 的患者在长期随访中需要进行系统修改,最常见的原因是需要 CRT 起搏。这些患者通过提取或放弃得到了成功的治疗。